Twenty-four men with benign prostate hyperplasia (BPH); 19 men with prostate cancer (PC) and five men with normal prostates (NP). Immunohistochemical and western blot analysis was performed. Serum levels of PSA were assayed by immulite autoanalyser.
In BPH and PC samples, immunoexpressions were observed for NF-¦ÊBp65 and NF-¦ÊBp50; while in NP samples, only were detected NF-¦ÊBp50. PC samples showed immunoreactions to NF-¦ÊBp65 and NF-¦ÊBp50 more intense (respectively 24.18 ¡À 0.67 and 28.23 ¡À 2.01) than that observed in BPH samples (respectively18.46 ¡À 2.04 and 18.66 ¡À 1.59) with special localisation in the nucleus. Different profiles of NF-¦ÊBp65 immunoexpressions were observed and BPH patients with sera PSA levels between 0-4 ng/mL presented a significant weak percentage compared to BPH patients with sera PSA levels between 4-20 ng/mL and > 20 ng/mL. No immunoreactions to NF-¦ÊBp65 were observed in PC patients with sera PSA levels between 4-20 ng/mL.
The sensibility of both NF-¦ÊB and PSA to inflammation allowed confirming the relationship between these two molecules and its involvement in prostatic diseases progression (inflammatory and neoplasic).